Saturday, June 25, 2016 1:37:33 PM
Next is the question about the shorts. As of now they are almost shorting 2.5 million shares. To me there seems only two plausible reasons these four hedge funds are shorting NNVC. They truly believe NNVC is either a fraud or the technology will never work. What doesn't make sense about that is the big risk in that bet for not a huge return. At any moment good or bad news will come out about NNVC making it jump up to $5 maybe $10 or fall down to pennies. The next reason is that they are getting paid to keep the price as low as possible so that at some point maybe after human trials a pharma company can buy NNVC at a low price. There's no way to tell which one is correct but one fact is that if NNVC comes out with good news the stock will jump up forcing the hedge funds to buy back $2.5 million shares which will explode the stock price.
What annoys me the most is that people should be talking about the products of NNVC more.
Facts:
The nanoviricides work with the virus not immune system so it doesn't matter the host.
They've gotten great results in thousands of animal tests with many of the drugs in their pipeline.
This is a cure for viruses. You shouldn't have expected NNVC to get it done right away. If you believed in it earlier you should believe in it now. Things have only gotten better.
Recent NNVC News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
- NanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York City • GlobeNewswire Inc. • 05/04/2023 10:45:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM